Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy

被引:55
作者
Lainka, E
Oezbek, S
Falck, M
Ndagijimana, J
Niehues, T
机构
[1] Univ Dusseldorf, Childrens Hosp, Paediat Immunol & Rheumatol Unit, D-4000 Dusseldorf, Germany
[2] Univ Dusseldorf, Clin Chem & Lab Res Unit, D-4000 Dusseldorf, Germany
关键词
antiretroviral therapy; HIV infection; dyslipidemia; carbohydrate metabolism;
D O I
10.1542/peds.110.5.e56
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. To assess the effects of antiretroviral combination therapy that contains protease inhibitor (PI) on carbohydrate and lipid metabolism in human immunodeficiency virus (HIV)-infected children. Methods. A cross-sectional, descriptive clinical study was conducted in an outpatient clinic. Thirty-seven HIV-infected children who ranged from 1 to 17 years of age received nucleoside reverse transcriptase inhibitor treatment together with PI (PI group, n = 25) or without PI (non-PI group, n = 12). Age, gender, weight, length, CD4 cell count, and viral load did not differ between groups. Nonfasting total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, lactate, and blood gases were determined. In addition, c-peptide, insulin, hemoglobin A1c, free fatty acids, lipoprotein a, and apolipoproteins A1 and B were evaluated after fasting. PI and non-PI group values were compared with normal values taken from healthy children. Results. In nonfasting and fasting conditions, children of the PI group had higher total cholesterol (fasting PI group: 235 +/- 71 mg/dL; non-PI group: 176 +/- 25 mg/dL, mean +/- standard deviation), triglycerides (156 +/- 89 vs 87 +/- 31 mg/dL), and LDL cholesterol levels (159 +/- 58 vs 113 +/- 23 mg/dL) compared with the non-PI group. High-density lipoprotein cholesterol and apolipoprotein A1 levels did not differ in both groups; there was a trend toward higher apolipoprotein B levels in the PI group. After fasting, 8 (47%) of 17 patients in the PI group presented with hypercholesterolemia as a result of an increase of LDL cholesterol and 11 (65%) had hypertriglyceridemia. It is interesting that the non-PI group showed no pathologic deviations. Compared with normal values, lipoprotein a and free fatty acids were increased in the PI and non-PI groups. Glucose, lactate, blood gases, c-peptide, insulin, and hemoglobin A1c were normal in both groups. Conclusion. PI-containing antiretroviral treatment of HIV-infected children was associated with hypercholesterolemia, hypertriglyceridemia, and an increase of LDL cholesterol. The long-term complications of dyslipidemia are of major concern in the growing HIV-infected child.
引用
收藏
页数:7
相关论文
共 34 条
[1]  
Abrams E., 2000, HIV CLIN TRIALS, DOI [10.1310/EC1D-A9JN-J0HB-24PY, DOI 10.1310/EC1D-A9JN-J0HB-24PY]
[2]   Lipodystrophy syndrome in human immunodeficiency virus-infected children [J].
Amaya, RA ;
Kozinetz, CA ;
McMeans, A ;
Schwarzwald, H ;
Kline, MW .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (05) :405-410
[3]  
Arpadi SM, 2001, J ACQ IMMUN DEF SYND, V27, P30, DOI 10.1097/00126334-200105010-00005
[4]   Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals [J].
Babl, FE ;
Regan, AM ;
Pelton, SI .
LANCET, 1999, 353 (9160) :1243-1244
[5]   Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy [J].
Barreiro, P ;
Soriano, V ;
Blanco, F ;
Casimiro, C ;
de la Cruz, JJ ;
González-Lahoz, J .
AIDS, 2000, 14 (07) :807-812
[6]  
BARTLETT JG, 2001, 2001 2002 MED MANAGE, P86
[7]   Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues [J].
Blanche, S ;
Tardieu, M ;
Rustin, P ;
Slama, A ;
Barret, B ;
Firtion, G ;
Ciraru-Vigneron, N ;
Lacroix, C ;
Rouzioux, C ;
Mandelbrot, L ;
Desguerre, I ;
Rötig, A ;
Mayaux, MJ ;
Delfraissy, JF .
LANCET, 1999, 354 (9184) :1084-1089
[8]   Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy [J].
Brambilla, P ;
Bricalli, D ;
Sala, N ;
Renzetti, F ;
Manzoni, P ;
Vanzulli, A ;
Chiumello, G ;
di Natale, B ;
Viganò, A .
AIDS, 2001, 15 (18) :2415-2422
[9]   Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[10]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86